↓ Skip to main content

Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib

Overview of attention for article published in Journal of Ophthalmic Inflammation and Infection, June 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
27 Mendeley
Title
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
Published in
Journal of Ophthalmic Inflammation and Infection, June 2015
DOI 10.1186/s12348-015-0049-9
Pubmed ID
Authors

Dafina Draganova, Joseph Kerger, Laure Caspers, François Willermain

Abstract

We report a case of severe bilateral panuveitis during melanoma therapy with a combination of Dabrafenib, a B-raf (BRAF) inhibitor, and Trametinib, a mitogen/extracellular signal-regulated kinase (MEK) inhibitor. Both of these drugs are effectors in the mitogen-activated protein kinase (MAPK) pathway, which plays an important role in the physiopathology of melanoma. Dabrafenib and Trametinib have shown improved survival of patients with metastatic melanoma but they have also been associated with the development of uveitis. Our patient was a 55-year-old woman with metastatic melanoma who presented with sudden onset of bilateral painless visual loss. She had been treated with Dabrafenib and Trametinib. Trametinib was discontinued at the onset of symptoms but there was no improvement. Ophthalmological examination revealed severe bilateral non-granulomatous panuveitis, with choroidal thickening, chorio-retinal folds, and multiple serous retinal detachments (SRDs). Topical corticosteroid treatment was initiated, and Dabrafenib was discontinued. A good response was obtained with a recovery of visual acuity of 20/25 on both eyes and an almost complete resolution of the SRDs. This case highly suggests that MAPK pathway inhibition can lead to severe uveitis. Dabrafenib and Trametinib could have both played a role in inducing the disease. Further studies are needed to evaluate the possible role of the combination of these drugs in inducing uveitis and SRD.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 4%
Unknown 26 96%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 7 26%
Other 6 22%
Student > Bachelor 2 7%
Student > Postgraduate 2 7%
Student > Master 2 7%
Other 3 11%
Unknown 5 19%
Readers by discipline Count As %
Medicine and Dentistry 18 67%
Nursing and Health Professions 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Unknown 7 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2015.
All research outputs
#4,336,406
of 5,208,530 outputs
Outputs from Journal of Ophthalmic Inflammation and Infection
#53
of 82 outputs
Outputs of similar age
#143,872
of 176,527 outputs
Outputs of similar age from Journal of Ophthalmic Inflammation and Infection
#4
of 5 outputs
Altmetric has tracked 5,208,530 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 82 research outputs from this source. They receive a mean Attention Score of 1.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,527 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.